A 17-year-old woman was admitted because of proteinuria, microhematuria and liver dysfunction with increased antinuclear antibody and anti-myeloperoxidase antibody (MPO-ANCA). Fourteen months' previously, urinalysis and liver function showed normal range. At that time she suffered from tachycardia and weight reduction, diagnosed as Graves' disease, she was given propylthiouracil for treatment of her Graves' disease. The histological finding of renal biopsy was compatible with minor glomerular abnormalities. Liver biopsy finding was compatible with autoimmune hepatitis. After we had administered prednisolone, liver function returned to normal range and urine protein became negative. Then we performed subtotal thyroidectomy, and she was not given propylthiouracil. MPO-ANCA decreased gradually. (Internal Medicine 43: 516-520, 2004) 
Introduction
Antithyroid drug therapy with thioamides, such as propylthiouracil (PTU) and methimazole, is commonly used in Graves' disease. Antithyroid drug therapy is often accompanied by several side effects, including a slight increase in liver enzymes, leukopenia, skin rash and arthralgias (1) . Vasculitis is a rare complication (2) . Antineutrophil cytoplasmic antibody (ANCA)-positive PTU-induced hypersensitivity vasculitis has been previously reported (2) . ANCA is directed to myeloid lysosomal enzymes and may be demonstrated in a cytoplasmic staining pattern or perinuclear stain-ing pattern by indirect immunofluorescence. The antimyeloperoxidase antibody (MPO-ANCA) directed at myeloperoxidase is associated with microscopic polyarteritis nodosa, idiopathic necrotizing and crescentic glomerulonephritis (3) . Autoimmune hepatitis is a disease of unknown etiology characterized by hypergammaglobulinemia and liver-related autoantibodies. Autoimmune hepatitis is subdivided into two major types: autoimmune hepatitis type 1 and type 2. ANCA has been found in 65 to 75% in patients with autoimmune hepatitis type 1 (4, 5) . Here, we report a case of Graves' disease accompanied by MPO-ANCA related nephropathy and autoimmune hepatitis.
Case Report
A 17-year-old woman suffered from tachycardia and weight reduction from 58 to 53 kg 8 months previously. A practitioner diagnosed her as suffering from Graves' disease due to increased free-T3 (10.84 pg/ml) and free-T4 (3.92 ng/dl), low TSH (0.01 U/ml) and increased TSH receptor binding antibody (TRAb) activity (54.3%). The practitioner gave her 30 mg of thiamazole daily and changed from thiamazole to 300 mg of PTU daily because of generalized itching 2 weeks after thiamazole administration. Hypothyroidism occurred during 150 mg of PTU daily intake. However, hyperthyroidism occurred after reduction of PTU (100 mg daily). PTU was then increased from 100 mg to 200 mg daily and she was brought to our hospital for Graves' disease treatment. At that time, as shown in Table 1 , urinalysis, hematology, liver function and renal function were within normal range. TSH; 0.01 U/ml, free-T3; 2.93 pg/ml, free-T4; 1.13 ng/dl, thyroglobulin; 1 ng/ml and TSH receptor binding antibody (TRAb); 22.9%. Three months' later we changed from 200 mg of PTU daily to 150 mg of PTU and added 50 g levothyroxine sodium daily. Six months' later she was shown urine protein positive and urine blood positive at her school health examination. There was no previous history of any disease other than Graves' disease.
Her physical examination showed the following findings: height 168 cm, weight 60 kg, blood pressure 124/67 mmHg, pulse rate 72/min and temperature 36.8°C. The thyroid was diffusely enlarged and elastic on palpation. There were no abnormalities in the chest. The liver was palpable 3 cm below the sternum, smooth and normal consistency. There was no skin eruption. Normal tendon reflexes and sensation were noted.
Laboratory data were as follows: chest X-ray film showed normal shadow. Electrocardiogram was shown within normal range. Abdominal echogram showed rough echo throughout the liver. Urinalysis showed blood (3+) and protein (30 mg/dl) with casts. Blood urea nitrogen; 13.6 mg/l, creatinine; 0.3 mg/dl, creatinine clearance; 120.1 ml/min, urine protein; 360 mg/day, AST; 251 mU/ml, ALT; 368 mU/ml, total bilirubin; 0.5 mg/dl, ZTT; 18.2 U, TTT; 7.6 U, HBsAg (-), anti-HCV Ab (-), anti-MPO antibody; 640 EU, anti-proteinase 3 (PR3) antibody; (-), anti-nuclear antibody; ×160, LE test (-), IgG; 2,888 mg/dl, IgA; 178 mg/dl, IgM; 429 mg/dl. TSH; 0.01 U/ml, free-T3; 3.06 pg/ml, free-T4; 1.47 ng/dl and TRAb; 38.6%. The methods used are as follows: anti-MPO antibody and anti-PR3 antibody were measured by enzyme-linked immunosorbent assay. Anti-nuclear antibody was measured by fluorescence antibody method.
The histological findings in renal biopsy showed slightly focal and segmental mesangial cell proliferation and mesangial matrix increase with normal tubules and interstitium ( Fig. 1A) , compatible with those of minor glomerular abnormalities. By immunofluorescence there was weak deposition of IgG (±), IgA (±), IgM (±), C3 (±) C1q (±), indicating a non-specific significance. By electron microscope there was slight basement membrane thickening and some mesangial matrix increase, indicating minor glomerular abnormalities. The histological findings in liver biopsy showed moderate disarrangement of the lobular structure with focal destruction of the limiting plate and moderate inflammatory cells in the portal area with moderate fibrosis (Fig. 1B antibody. Therefore, the clinical diagnosis was autoimmune hepatitis. She had been administered 30 mg of prednisolone daily for a month and liver function had returned to normal range after the 10th day. We then performed subtotal thyroidectomy, the histological finding of which showed diffuse thyroid follicular hyperplasia with sporadic lymphocyte infiltration in the interstitium, compatible with histological findings of Graves' disease. After that we had not given her PTU. Although we had reduced prednisolone by 5 mg every month, liver function remained normal and urine protein became negative, however, urine blood was positive. MPO-ANCA decreased gradually (Fig. 2 ).
Discussion
The patient had featured Graves' disease accompanied by minor glomerular abnormalities and autoimmune hepatitis during PTU treatment. Graves' disease was diagnosed by increased free-T3 and free-T4, depressed TSH and high TRAb activity. Minor glomerular abnormalities were diagnosed by microhematuria, proteinuria and histological finding in the renal biopsy. Although liver dysfunction may be due to PTU induced hepatic injury, most cases of PTU-induced hepatic injury occur in the first few months of PTU therapy (6) . Liver function had been within normal range in the first 8 months of PTU in the present case. The histological type of PTU-induced hepatic injury is classified as cholestatic, hepatocellular and mixed form (6) . Histological findings in the liver biopsy showed chronic active hepatitis, which were compatible with those of autoimmune hepatitis, not with those of PTU-induced hepatic injury.
The patient suffered from Graves' disease. During PTU treatment, ANCA related nephritis and autoimmune hepatitis had occurred overtly. The question is why the patient has these three different autoimmune diseases. Although the pathogenesis of these diseases has not yet been elucidated, it may be important to find a common immunological abnormality underlying the development of these three diseases. PTU has been shown to induce ANCA related vasculitis. PTU has been shown to accumulate in neutrophils (7) , bind to myeloperoxidase and change its structure (8) . This alteration in configuration may allow initiation of autoantibody formation.
Although MPO-ANCA related nephritis often causes an irreversible renal dysfunction after crescentic glomerulonephritis occurrence (9), the present case had minor glomerular abnormalities. Concomitant occurrence of Graves' disease and minor glomerular abnormalities in the absence of any other immunologic abnormalities has been shown (10), however, the present case showed various immnologic abnormalities. Although there is a high frequency of MPO-ANCA in patients with Graves' disease treated with PTU, classical ANCA-associated vasculitis develops in only a few MPO-ANCA positive patients (11, 12) . Recently positive ANCA has been described in patients with autoimmune hepatitis (4, 5) . Perinuclear ANCA has been recently defined as the most sensitive autoantibody of autoimmune hepatitis type 1. Autoimmune hepatitis type 2 is characterized by antibodies to liver/kidney microsome type 1. The presence of perinuclear ANCA seems to be an independent and sensitive marker for autoimmune hepatitis type 1 (13) . MPO is the major antigen of perinuclear ANCA (3). The diagnosis of the present MPO-ANCA positive case indicates autoimmune hepatitis type 1. Graves' disease-associated autoimmune hepatitis has been shown (14) . However, those reports did not include the ANCA level. Whether these three autoimmune disorders occurred by common genetic factors or Graves' disease accompanied by PTU induced ANCA related nephritis or autoimmune hepatitis is un- known, however, it may be important to investigate ANCA and Graves' disease.
